


134991

Translational Medicine Series 4



Multiple Myeloma

Translational and Emerging Therapies

Edited by

Kenneth C. Anderson

Irene M. Ghobrial

informa
healthcare

Preface iii

Contributors vii

1. Xenograft Animal Models for Preclinical Evaluation of Potential Anti-MM Therapeutics: Strengths and Limitations **I**
Constantine S. Mitsiades, Kenneth C. Anderson, and Daniel R. Carrasco
2. The Role of the Bone Marrow Microenvironment in the Pathogenesis of Multiple Myeloma **23**
Teru Hideshima and Noopur Raje
3. Myeloma Bone Disease **45**
Alissa Huston and G. David Roodman
4. Niches Within the Multiple Myeloma Bone Marrow Microenvironment **61**
Klaus Podar, Irene Ghobrial, Teru Hideshima, Dharminder Chauhan, and Kenneth C. Anderson
5. Novel Therapeutic Targets in Multiple Myeloma **75**
Giovanni Tonon
6. Monoclonal Gammopathy of Undetermined Significance **95**
Robert A. Kyle and S. Vincent Rajkumar
7. Prognostic Factors and Classification in Multiple Myeloma **115**
Jesús F. San Miguel, Ramón García-Sanz, and Norma C. Gutiérrez
8. Novel Agents for Previously Untreated Multiple Myeloma **141**
Sheeba Thomas, Tiffany Richards, and Donna M. Weber
9. Novel Therapeutic Options for the Treatment of Relapsed and Relapsed, Refractory Myeloma **169**
Melissa Alsina and Paul Richardson
10. High-Dose Therapy in Multiple Myeloma **197**
Jean-Luc Harousseau

11. Promising New Agents in Phase I and II Clinical Trials in Multiple Myeloma **211**
Xavier Leleu and Kenneth C. Anderson
12. Immunotherapeutic Strategies for the Management of Multiple Myeloma **243**
Rao H. Prabhala, Dheeraj Pelluru, and Nikhil C. Munshi
13. Novel Therapeutic Options in Primary Systemic Amyloidosis **261**
Morie A. Gertz
14. Novel Options of Therapy in Waldenström Macroglobulinemia **277**
Irene M. Ghobrial, Anne-Sophie Moreau, Xavier Leleu, and Meletios A. Dimopoulos